Physician profile
Nosheen Mian
NPI 1376631689
$4,981.79
in general payments reported to CMS, 2019-2025
33 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $913 · 2021: $463 · 2022: $364 · 2023: $852 · 2024: $1,098 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $655.83 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $630.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $598.04 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $504.11 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $370.66 | 2019-2021 | |
| Pfizer INC. | $339.56 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.47 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $192.57 | 2019-2021 | |
| Abbvie INC. | $187.24 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.05 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $122.25 | 2019-2024 | Trelegy Ellipta |
| Allergan, INC. | $112.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $89.54 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $71.54 | 2022-2023 | Quviviq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $67.33 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $60.32 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $57.37 | 2020-2024 | |
| Boston Scientific Corporation | $54.24 | 2024 | Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $40.26 | 2020-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $37.94 | 2019-2024 | Xarelto |
| Xeris Pharmaceuticals, INC. | $36.92 | 2022-2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $35.22 | 2019-2025 | Trintellix |
| Eisai INC. | $31.75 | 2020 | |
| Ironwood Pharmaceuticals, INC | $31.51 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $31.19 | 2020 | |
| Esperion Therapeutics, INC. | $27.97 | 2021-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $27.79 | 2019-2021 | |
| Evofem Biosciences, INC. | $24.02 | 2022 | |
| Lundbeck LLC | $21.14 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $19.08 | 2022 | |
| Sanofi Pasteur INC. | $13.15 | 2020 | |
| Kinex Medical Company LLC | $4.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nosheen Mian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.